Patient and disease characteristics
| Characteristic at time of sampling, n (%) . | All patients,170 (100) . | De novo,66 (39) . | On therapy,104 (61) . |
|---|---|---|---|
| Female/male | 72/98 (42/58) | 26/40 (39/61) | 46/58 (44/56) |
| Median age at diagnosis, y | 51.5 | 53.5 | 50.0 |
| Disease stage | |||
| Chronic phase | 151 (89) | 61 (92) | 90 (87) |
| Accelerated phase | 16 (9) | 5 (8) | 11 (10) |
| Blastic crisis | 3 (2) | 0 (0) | 3 (3) |
| Cytogenetics | |||
| t(9;22) only | 146 (86) | 55 (83) | 91 (87) |
| Additional abnormalities | 24 (14) | 11 (17) | 13 (13) |
| Median disease duration, mo | 31 | 8 | 52 |
| Median duration on imatinib, mo | 43 | 7 | 47 |
| Treatment | |||
| Imatinib mesylate | 170 (100) | 66 (100) | 104 (100) |
| Interferon | 34 (20) | 0 (0) | 34 (33) |
| Bone marrow transplantation | 11 (6) | 1 (2) | 10 (10) |
| Characteristic at time of sampling, n (%) . | All patients,170 (100) . | De novo,66 (39) . | On therapy,104 (61) . |
|---|---|---|---|
| Female/male | 72/98 (42/58) | 26/40 (39/61) | 46/58 (44/56) |
| Median age at diagnosis, y | 51.5 | 53.5 | 50.0 |
| Disease stage | |||
| Chronic phase | 151 (89) | 61 (92) | 90 (87) |
| Accelerated phase | 16 (9) | 5 (8) | 11 (10) |
| Blastic crisis | 3 (2) | 0 (0) | 3 (3) |
| Cytogenetics | |||
| t(9;22) only | 146 (86) | 55 (83) | 91 (87) |
| Additional abnormalities | 24 (14) | 11 (17) | 13 (13) |
| Median disease duration, mo | 31 | 8 | 52 |
| Median duration on imatinib, mo | 43 | 7 | 47 |
| Treatment | |||
| Imatinib mesylate | 170 (100) | 66 (100) | 104 (100) |
| Interferon | 34 (20) | 0 (0) | 34 (33) |
| Bone marrow transplantation | 11 (6) | 1 (2) | 10 (10) |